Core Viewpoint - The clinical trial for LZ901 vaccine conducted in the United States has successfully completed Phase I, demonstrating good safety and immunogenicity in both high and low dose groups compared to the placebo group, laying the groundwork for further clinical research [1] Group 1: Clinical Trial Results - The Phase I clinical trial of LZ901 vaccine showed good safety and immunogenicity in both high and low dose groups compared to the placebo group [1] - The primary objective of the trial was to verify the vaccine's safety, with only the low dose group experiencing mild adverse reactions (4.35%), while no adverse reactions were reported in the high dose and placebo groups [1] Group 2: Product Development - LZ901 is a recombinant shingles vaccine developed by the company, aimed at preventing shingles and related complications in adults aged 40 and above [1] - The vaccine has achieved its clinical preset goals in a Phase III trial conducted in China and has obtained expected clinical results [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation [1]
绿竹生物-B(02480)于美国成功完成LZ901的I期临床试验